Flu News and Research

RSS

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

Generex Biotechnology Corporation today announced presentations in respect of the technologies and development products of its wholly-owned subsidiary, Antigen Express, Inc. The presentations were made at the conference Gene based Vaccines: Optimizing Development and Delivery 2010 held September 13 and 14, 2010 in Vienna, Austria and at the Immunotherapeutics and Vaccine Summit held in Cambridge, MA from August 17-19, 2010.

17 Sep 2010

LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company focused on the development of innovative vaccine products, announced today that it has initiated the first clinical trial for its bivalent intramuscular (IM) norovirus vaccine candidate, marking the fourth human clinical trial in the Company's norovirus virus-like particle (VLP) vaccine program.

17 Sep 2010

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic resistant infections, delivered four poster presentations on its Aganocide compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA.

16 Sep 2010

Friendship paradox helps analyze social network, monitor member health to predict flu outbreak

Nicholas Christakis, professor of medicine, medical sociology and sociology at Harvard University, and James Fowler, professor of medical genetics and political science at the University of California, San Diego, used the paradox to study the 2009 flu epidemic among 744 students. The findings, the researchers say, point to a novel method for early detection of contagious outbreaks.

16 Sep 2010

Researchers investigate antimicrobial activity of Aganocide compounds against H1N1

Fears over the influenza A virus (H1N1; sometimes referred to as swine flu) have motivated researchers to investigate the antimicrobial activity of the Aganocide compounds against viruses. In a study presented at this year's Interscience Conference on Antimicrobial Agents and Chemotherapy, a team led by Professor Markus Nagl, MD of Medical University of Innsbruck and including D. Debabov, PhD and K. Hybiske, PhD of NovaBay Pharmaceuticals evaluated the in vitro virucidal activity of three compounds: N-chlorotaurine, a compound produced by human phagocytes; and two NCT analogs, NVC-612 and NVC-422.

16 Sep 2010

Doctors demonstrate the true impact of vaccination

With Children Back in School, Doctors Clear up Confusion and Demonstrate the True Impact of Vaccination

16 Sep 2010

Scientia Advisors reviews growth in POC market

Rapid medical tests that can be analyzed in close proximity to patients in professional settings comprise the fastest growing segment of the global $37.5B in-vitro diagnostics industry, according to a new global review of the point-of-care (POC) diagnostics industry.

15 Sep 2010

Resident doctors report working when sick

A new study demonstrates that young doctors often fail to heed the Biblical injunction, "physician, heal thyself." In a research letter published in the September 15, 2010, issue of JAMA, researchers report that three out of five residents surveyed came to work in the previous year while sick, possibly exposing their patients and colleagues to suboptimal performance and, in many cases, communicable disease.

15 Sep 2010

ITS commences treatment in synthetic universal influenza vaccine Phase I trial

Immune Targeting Systems (ITS) Limited, one of the leading developers of synthetic vaccines for mutating viruses, today announced the first patient has been treated in its Phase-I trial with its synthetic universal influenza vaccine (FP-01). Commencement of trials follows receipt of UK Regulatory Authority (MHRA) approval. Over the same period the company brought in £500,000 new investment from Esperante Ventures (UK).

15 Sep 2010

MVI agrees to provide fund for evaluating Inovio's malaria DNA vaccine candidate in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has agreed to provide follow-on funding to continue evaluation and development of Inovio's malaria DNA vaccine candidate in non-human primates.

15 Sep 2010

Pregnant women should get immunized against flu

There will be only one flu shot needed this year and pregnant women should make sure they're at the front of the line to get it.

15 Sep 2010

Opinions: Global nursing; U.S. funding of Global Fund; Global demands for water; Food security

"Almost every nation, regardless of its wealth and resources, faces a continuing shortage of nurses and an acute lack of nursing faculty available to educate more nurses. This dearth of practicing nurses and nurse educators is particularly critical in countries like Haiti and other developing high-risk, low-resourced nations," Martha Hill, dean of Johns Hopkins School of Nursing, writes in a Baltimore Sun opinion piece encouraging the expansion of global nursing.

15 Sep 2010

More adults washing hands in public restrooms

In the latest observational study sponsored by the American Society for Microbiology and the American Cleaning Institute- (formerly The Soap and Detergent Association), 85% of adults washed their hands in public restrooms, compared with 77% in 2007. The 85% total was actually the highest observed since these studies began in 1996. The results were announced at the Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting sponsored by the American Society for Microbiology.

14 Sep 2010

New book relates mercury in vaccines to autism

The U.S. government revealed last week that they will compensate a family millions of dollars for their daughter's injury related to her infant vaccines that contained mercury and the subsequent development of autism. Yet, the CDC continues to tell the public that there is no connection between vaccines and autism and that the mercury has been removed, although the flu shot recommended for all pregnant women, infants, and children continues to be preserved with mercury.

13 Sep 2010

Researchers develop mathematical framework for vaccine stockpile implications

A creative version of a classic engineering technique may improve decisions about building and using supplies of important pediatric vaccines, potentially leading to lower public health costs and healthier children.The United States maintains a six-month supply of common pediatric vaccines to ensure protection from deadly diseases, such as the flu, polio, and diphtheria, despite interruptions in vaccine production.

13 Sep 2010

NanoBio Corporation to present Nanoemulsion Phase I clinical trial data at ICAAC Conference

NanoBio Corporation today announced it will present data from two separate Phase 1 clinical trials at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Boston, Mass. from Sept. 12-15.

13 Sep 2010

Disinfectant hand gels not effective against Swine flu: Study

According to the latest research published this Sunday, regular use of alcohol-based disinfecting hand gels has little effect on the H1N1 swine flu infection rates. The authors of the study said that the infection is spread by air droplets rather than touch and contact.

12 Sep 2010

56% of Australians won’t vaccinate against Swine flu: Survey

Over fifty per cent of Australians were not vaccinated against the swine flu before winter arrived this year, with many of these people deliberately choosing not to be vaccinated.

9 Sep 2010

SDI's VaccineTrack data reports on season's flu vaccination

More than 690,000 Americans have already received this season's flu vaccine from their doctor, according to SDI's VaccineTrack data through Sept. 4. VaccineTrack provides syndicated weekly vaccine usage by physicians based on medical office electronic healthcare reimbursement claims data.

9 Sep 2010

Synthetic biology survey reveals need for attention towards addressing biosafety, biosecurity risks

Synthetic biology defined as the design and construction of new biological parts, devices, and systems or re-design of existing natural biological systems for useful purposes holds enormous potential to improve everything from energy production to medicine, with the global market projected to reach $4.5 billion by 2015.

9 Sep 2010

Flu News and Research

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

Friendship paradox helps analyze social network, monitor member health to predict flu outbreak

Researchers investigate antimicrobial activity of Aganocide compounds against H1N1

Doctors demonstrate the true impact of vaccination

Scientia Advisors reviews growth in POC market

Resident doctors report working when sick

ITS commences treatment in synthetic universal influenza vaccine Phase I trial

MVI agrees to provide fund for evaluating Inovio's malaria DNA vaccine candidate in non-human primates

Pregnant women should get immunized against flu

Opinions: Global nursing; U.S. funding of Global Fund; Global demands for water; Food security

More adults washing hands in public restrooms

New book relates mercury in vaccines to autism

Researchers develop mathematical framework for vaccine stockpile implications

NanoBio Corporation to present Nanoemulsion Phase I clinical trial data at ICAAC Conference

Disinfectant hand gels not effective against Swine flu: Study

56% of Australians won’t vaccinate against Swine flu: Survey

SDI's VaccineTrack data reports on season's flu vaccination

Synthetic biology survey reveals need for attention towards addressing biosafety, biosecurity risks

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News